Respiratory molecular testing has transformed clinical medicine.

Modern PCR platforms can rapidly identify specific respiratory pathogens with remarkable analytical sensitivity, providing information that can materially affect treatment, infection prevention, isolation, and other clinical decisions.

For many patients, that information is important. For some, it is essential.

But diagnostic stewardship requires healthcare organizations to ask a different question:

What information does the clinician actually need to manage this patient?

If identifying a specific pathogen is expected to change management, molecular testing may be exactly the right diagnostic tool.

But when the primary clinical uncertainty is whether an acute respiratory infection is bacterial or non-bacterial—and whether antibacterial therapy may be appropriate—identifying a broad array of individual pathogens may not always be necessary.

That distinction creates an important opportunity for hospitals.

The objective is not to replace PCR with a less expensive test.

It is to match the diagnostic strategy to the clinical question—and reserve increasingly sophisticated diagnostics for the patients in whom the additional information is expected to create clinical value.

With FebriDx now FDA 510(k)-cleared and CLIA-waived, healthcare organizations have another diagnostic option to consider within that strategy.

The Clinical Question Comes First

FebriDx and molecular PCR testing should not be viewed as interchangeable diagnostics.

They provide different information.

PCR is pathogen-directed. Depending on the assay, molecular testing can detect nucleic acid from specific respiratory viruses and bacteria and help clinicians determine which pathogen may be present.

FebriDx does not identify a specific organism.

Instead, FebriDx measures two host-response biomarkers—myxovirus resistance protein A, or MxA, and C-reactive protein, or CRP—to aid in differentiating bacterial acute respiratory infection from non-bacterial etiology.

FebriDx is an FDA 510(k)-cleared, CLIA-waived, instrument-free point-of-care assay using fingerstick blood, with a result available after approximately 10 minutes.

The distinction can be summarized simply:

PCR asks: What pathogen can we detect?

FebriDx asks: What does the host response suggest about bacterial versus non-bacterial etiology?

Neither question is inherently more important.

The appropriate question depends on the patient.

That is the foundation of diagnostic stewardship.

More Information Does Not Automatically Mean More Clinical Value

Healthcare understandably tends to associate more diagnostic information with better care.

But the amount of information generated by a test and the clinical value of that information are not the same thing.

A highly accurate test can still represent low-value utilization when its result is unlikely to change management.

Conversely, an expensive molecular test can represent extremely high-value care when identifying a pathogen materially affects treatment or another important clinical decision.

The relevant question is therefore not simply:

How much information does this test provide?

It is:

Will this information change what we do for this patient?

This distinction becomes particularly important with broad molecular respiratory panels.

If identifying the pathogen will influence antiviral treatment, infection-control measures, additional diagnostic evaluation, or another important aspect of care, the additional information may fully justify molecular testing.

But if the immediate decision is primarily whether the clinical picture supports bacterial infection and whether antibacterial therapy is appropriate, a different diagnostic approach may sometimes provide information more closely aligned with that question.

That is where host-response testing becomes relevant.

Hospitals Are Already Finding Savings Through Molecular-Test Stewardship

The opportunity to optimize respiratory molecular testing is not theoretical.

Recent health-system studies have demonstrated that more selective molecular-testing strategies can materially reduce utilization and laboratory expense.

A 2026 study in Microbiology Spectrum evaluated an integrated safety-net health system that transitioned from widespread use of a multiplex respiratory pathogen PCR panel to selective use.

During two years of unrestricted testing, the system performed 8,923 respiratory pathogen panels. During the first year of selective use, it performed 184.

Median weekly testing declined from 83 panels to three, and annualized laboratory costs associated with the panel declined from approximately $741,000 to approximately $31,000. The percentage of panels with at least one detected target did not significantly change.

Another 2026 health-system initiative used clinical decision support to encourage smaller respiratory panels when clinically appropriate and reported approximately $2.26 million in reagent savings.

A separate diagnostic-stewardship initiative targeting multiplex pneumonia PCR panels reported a 34% reduction in testing. Using the study's estimated $200 cost per panel, investigators calculated savings of at least $208,000.

These findings are important—but so is what they do not establish.

These studies demonstrate the economic potential of respiratory diagnostic stewardship. They do not establish that substituting FebriDx for molecular testing would produce comparable savings.

That question must be evaluated prospectively within each health system's patient population, clinical pathways, utilization patterns, and cost structure.

Published savings figures should also not be treated as transferable unit economics. The financial opportunity for an individual organization depends on its actual reagent costs, laboratory structure, reimbursement, payer mix, test volume, contractual arrangements, and the extent to which reduced utilization translates into genuinely avoidable expense.

The lesson is therefore not that PCR is too expensive.

It is that inappropriate or unnecessarily broad diagnostic utilization can be expensive.

Where FebriDx May Fit

FebriDx approaches respiratory diagnostic uncertainty differently from molecular testing.

Rather than identifying pathogen genetic material, it evaluates the host response through MxA and CRP.

The assay therefore does not tell the clinician that a patient has influenza, RSV, SARS-CoV-2, or another specific pathogen.

It provides information intended to aid differentiation between bacterial acute respiratory infection and non-bacterial etiology.

The manufacturer's materials appropriately describe FebriDx as complementary to existing diagnostic pathways rather than as a replacement for pathogen testing.

That distinction suggests a potential diagnostic framework:

Clinical assessment → define the clinical question → select the diagnostic approach most appropriate to that question → escalate or add testing when additional information is expected to change management

Within that framework, an appropriately selected patient whose primary clinical uncertainty is bacterial versus non-bacterial etiology may be a candidate for host-response testing.

A patient for whom pathogen identification will influence management may require targeted or multiplex molecular testing.

Other patients may appropriately require both forms of information—or additional diagnostic evaluation.

This is not a proposed clinical protocol.

It is a framework that hospitals can evaluate through infectious disease, laboratory medicine, emergency medicine, ambulatory care, and antimicrobial stewardship leadership.

When Molecular Testing Is the Right Choice

A credible diagnostic-stewardship strategy should never begin with the objective of reducing PCR simply because PCR costs more.

It should begin with the objective of using molecular testing appropriately.

There are many situations in which pathogen identification can be clinically important.

Depending on the patient and clinical circumstances, molecular testing may affect antiviral therapy, infection-prevention or isolation decisions, evaluation of severe respiratory illness, management of immunocompromised patients, public-health considerations, additional diagnostic evaluation, or other treatment decisions.

In those circumstances, the information generated by molecular testing may justify its cost many times over.

This is why diagnostic stewardship should not be confused with diagnostic restriction.

The objective is not to deny clinicians useful information.

It is to ensure that the information being purchased is likely to contribute meaningfully to care.

Molecular sensitivity and clinical specificity are also not synonymous. Highly sensitive molecular testing can sometimes detect nucleic acid whose clinical significance still requires interpretation. That is not a weakness unique to PCR; it is another reason sophisticated diagnostics must always be interpreted within the patient's clinical context.

The Better Economic Metric May Be Cost per Clinically Useful Decision

Comparing the acquisition price of FebriDx with the price of a PCR panel would provide an incomplete—and potentially misleading—economic analysis.

The relevant economic unit may not be cost per test.

It may be cost per clinically useful decision.

Consider two hypothetical examples.

A relatively inexpensive test that fails to answer the clinical question and leads to additional laboratory testing, imaging, delayed treatment, or another encounter may ultimately create more cost.

Conversely, an expensive molecular panel that identifies a pathogen and immediately changes treatment may represent excellent value.

The financial question is therefore not:

Which test costs less?

It is:

What diagnostic pathway provides the information necessary to make an appropriate clinical decision at the lowest total cost without compromising patient care?

That requires looking beyond the test itself.

A meaningful analysis should consider:

• direct test and reagent expense,
• laboratory labor and processing,
• analyzer and capital-equipment requirements,
• service and maintenance,
• specimen collection and transportation,
• turnaround time,
• downstream diagnostic utilization,
• antibiotic utilization,
• reimbursement and payer mix,
• patient throughput,
• repeat encounters,
• and whether the diagnostic result actually changes management.

FebriDx has a materially different operational profile from molecular testing.

It is self-contained and instrument-free. Supporting materials describe less than one minute of hands-on time, with no analyzer or routine instrument calibration or maintenance.

The assay uses fingerstick blood and provides a result after approximately 10 minutes.

Those characteristics do not establish that FebriDx is economically superior to PCR.

They do mean that it belongs in a different economic model.

CLIA-Waived Status Changes the Implementation Equation

The CLIA waiver makes that operational distinction more significant.

FebriDx can be performed in appropriately authorized waived-testing settings without requiring moderate- or high-complexity laboratory certification for the assay.

That potentially allows host-response testing to be deployed closer to where many respiratory treatment decisions occur.

For a health system with multiple emergency departments, urgent care centers, primary care practices, ambulatory clinics, or other eligible point-of-care environments, scalability matters.

A diagnostic strategy requiring an analyzer, capital investment, specialized laboratory infrastructure, and more complex operational requirements can have very different system-wide economics from an instrument-free point-of-care assay.

But CLIA-waived does not mean oversight-free.

Waived sites remain responsible for appropriate certification, staff training, quality-control procedures, documentation, oversight, adherence to the FDA-cleared Instructions for Use, and other applicable requirements. FebriDx implementation materials specifically address external controls, operator procedures, quality documentation, and related responsibilities.

The advantage is therefore not the absence of a quality system.

It is a different level of diagnostic infrastructure.

Scale Can Turn Utilization Into a Strategic Financial Issue

The economics become more significant when viewed across an entire health system.

A hospital network may evaluate thousands or tens of thousands of patients with acute respiratory symptoms each year across emergency departments, urgent care centers, primary care offices, and ambulatory locations.

Small changes in diagnostic utilization can therefore compound rapidly.

But volume alone does not establish a savings opportunity.

Leadership first needs to understand its current state:

How many respiratory molecular tests are being performed?

Which panels are being ordered?

In what patient populations?

What is the actual marginal cost?

How frequently does the result change management?

How often could a more targeted diagnostic strategy have appropriately answered the clinical question?

And what happens downstream when testing is reduced or changed?

Those questions turn a theoretical savings discussion into an actionable diagnostic-stewardship analysis.

Test the Hypothesis Rather Than Assume the Savings

The strongest way to determine whether FebriDx can contribute to a more efficient respiratory diagnostic pathway is to measure it prospectively.

A health system could identify selected emergency department, urgent care, or ambulatory populations in which bacterial versus non-bacterial uncertainty frequently influences treatment decisions.

Before implementation, leadership could establish baseline measures such as:

• respiratory molecular tests per 1,000 eligible encounters,
• broad versus targeted panel utilization,
• diagnostic expense per eligible respiratory encounter,
• antibiotic prescribing,
• turnaround time,
• repeat visits,
• escalation of care,
• hospital admissions,
• provider-level variation,
• and other patient-safety outcomes.

FebriDx could then be incorporated into a defined clinical pathway for appropriately selected patients, with molecular testing preserved whenever pathogen identification is clinically important.

The organization could then determine what actually changes.

Success should not be defined by the number of FebriDx tests performed.

It should not even be defined solely by a reduction in PCR utilization.

The relevant questions are broader:

Did unnecessary molecular testing decline?

Was clinically appropriate molecular testing preserved?

Did total diagnostic expense per eligible encounter change?

Did antibiotic decision-making improve?

Were patient-safety outcomes maintained?

Did downstream diagnostic utilization change?

Was the result available early enough to influence treatment?

Did clinicians accept and follow the pathway?

And, ultimately:

Did the organization create more clinical value for each diagnostic dollar spent?

The CMO and CFO Should Be Asking the Same Question

Diagnostic stewardship is one of those areas where clinical and financial stewardship should naturally align.

The CMO might ask:

Are we ordering the most clinically appropriate diagnostic test for this patient?

The CFO might ask:

Are we paying for diagnostic information that materially contributes to care?

Those are not competing priorities.

They are two perspectives on the same resource-allocation decision.

The correct sequence matters.

Clinical appropriateness should determine utilization. Utilization then determines economics.

Cost reduction should not dictate the clinical pathway.

But when a clinically appropriate pathway also avoids testing that does not add sufficient value, better care and better resource stewardship can coexist.

That is a much more sustainable approach to healthcare cost reduction than simply negotiating a lower price per test.

From Lower-Cost Testing to Higher-Value Diagnosis

The future of respiratory diagnostics should not become a contest between PCR and host-response testing.

Hospitals need access to sophisticated molecular diagnostics.

They also need disciplined utilization.

For some patients, clinical assessment may be sufficient.

For others, targeted pathogen testing may be appropriate.

For selected patients in whom bacterial versus non-bacterial uncertainty is influencing treatment, host-response testing may provide useful additional information.

And for patients in whom pathogen identification materially affects management, molecular testing may be exactly the right choice.

The opportunity created by FebriDx's CLIA-waived status is therefore larger than a simple test-price comparison.

It gives healthcare organizations another diagnostic option that can potentially be incorporated into a more targeted, clinically driven respiratory pathway.

Could that pathway reduce unnecessary molecular testing?

Could it lower total diagnostic expense?

Could it support more appropriate antibiotic use?

Could it preserve sophisticated molecular testing for the patients who benefit from the information it provides?

Those questions should be answered with prospective clinical and financial data rather than assumptions.

Because diagnostic stewardship is not about performing fewer tests simply to save money.

It is about ensuring that each test provides enough clinical value to justify the resources required to perform it.

The objective should not be cheaper testing.

It should be higher-value diagnosis.

About FebriDx

FebriDx is an FDA 510(k)-cleared, CLIA-waived, prescription-use point-of-care assay that measures the host-response biomarkers MxA and CRP from fingerstick blood to aid in differentiating bacterial acute respiratory infection from non-bacterial etiology.

Current product materials specify use in patients ages 12 through 64 presenting with symptoms of acute respiratory infection for less than seven days and within three days of fever onset.

FebriDx does not identify specific pathogens and should not be considered a replacement for pathogen-directed testing when organism identification is clinically necessary.

About CG Moneta Consulting

CG Moneta Consulting (CGM) is a vendor-agnostic healthcare consulting and advisory firm that helps healthcare organizations evaluate financial, operational, technology, and clinical opportunities.

CGM works with provider organizations to determine where emerging solutions can create measurable value and whether they align with an organization's clinical, operational, and financial priorities.

Through its strategic relationships, CGM also supports healthcare organizations evaluating FebriDx and its potential role within point-of-care respiratory diagnostics and antimicrobial stewardship initiatives.

Clinical and Regulatory Note

FebriDx should be used in accordance with its FDA-cleared labeling and Instructions for Use. Results are intended to support—not replace—clinical judgment and should be interpreted in the context of the patient's presentation and other clinically appropriate diagnostic information.

FebriDx does not diagnose specific pathogens, eliminate the need for other testing, or establish that molecular testing is unnecessary in an individual patient. CLIA-waived sites remain responsible for applicable certification, training, quality control, documentation, oversight, and compliance requirements.

Selected References

Jenkins TC, Young HL, Wyles DL, et al. Effects of a diagnostic stewardship intervention to de-implement widespread use of a rapid respiratory multiplex PCR test. Microbiology Spectrum. 2026.

DiLorenzo M, Marsh K, Wang G, et al. Diagnostic stewardship of a multiplex pneumonia PCR panel leads to cost savings and more appropriate patient care. Antimicrobial Stewardship & Healthcare Epidemiology. 2026.

Lucar J, Yee R. Diagnostic Stewardship for Multiplex Respiratory Testing: What We Know and What Needs to Be Done. Clinical Laboratory Medicine. 2024;44(1):45–61.

Shapiro NI, Filbin MR, Hou PC, et al. Diagnostic Accuracy of a Bacterial and Viral Biomarker Point-of-Care Test in the Outpatient Setting. JAMA Network Open. 2022;5(10):e2234588.